213 related articles for article (PubMed ID: 25982178)
1. Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy.
Drolle H; Wagner M; Vasold J; Kütt A; Deniffel C; Sotlar K; Sironi S; Herold T; Rieger C; Fiegl M
Leuk Res; 2015 Jul; 39(7):779-85. PubMed ID: 25982178
[TBL] [Abstract][Full Text] [Related]
2. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
[TBL] [Abstract][Full Text] [Related]
3. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
[TBL] [Abstract][Full Text] [Related]
4. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia.
Kuett A; Rieger C; Perathoner D; Herold T; Wagner M; Sironi S; Sotlar K; Horny HP; Deniffel C; Drolle H; Fiegl M
Sci Rep; 2015 Dec; 5():18411. PubMed ID: 26674118
[TBL] [Abstract][Full Text] [Related]
5. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
Tafuri A; Lemoli RM; Chen R; Gulati SC; Clarkson BD; Andreeff M
Leukemia; 1994 May; 8(5):749-57. PubMed ID: 7514244
[TBL] [Abstract][Full Text] [Related]
6. Microenvironmental oxygen partial pressure in acute myeloid leukemia: Is there really a role for hypoxia?
Rieger CT; Fiegl M
Exp Hematol; 2016 Jul; 44(7):578-82. PubMed ID: 27118044
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
[TBL] [Abstract][Full Text] [Related]
8. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
9. The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling.
Forte D; Salvestrini V; Corradi G; Rossi L; Catani L; Lemoli RM; Cavo M; Curti A
Oncotarget; 2017 Jan; 8(2):2261-2274. PubMed ID: 27903985
[TBL] [Abstract][Full Text] [Related]
10. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
11. Targeting the microenvironment in acute myeloid leukemia.
Rashidi A; Uy GL
Curr Hematol Malig Rep; 2015 Jun; 10(2):126-31. PubMed ID: 25921388
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-CXCL6 axis affects arteriolar niche remodeling in acute myeloid leukemia.
Li L; Man J; Zhao L
Exp Biol Med (Maywood); 2021 Jan; 246(1):84-96. PubMed ID: 33167688
[TBL] [Abstract][Full Text] [Related]
13. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
te Boekhorst PA; Löwenberg B; Vlastuin M; Sonneveld P
Leukemia; 1993 Aug; 7(8):1191-8. PubMed ID: 7688839
[TBL] [Abstract][Full Text] [Related]
14. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
Wang A; Zhong H
Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
[TBL] [Abstract][Full Text] [Related]
15. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
Park S; Chapuis N; Bardet V; Tamburini J; Gallay N; Willems L; Knight ZA; Shokat KM; Azar N; Viguié F; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Leukemia; 2008 Sep; 22(9):1698-706. PubMed ID: 18548104
[TBL] [Abstract][Full Text] [Related]
16. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia.
Jenkins C; Hewamana S; Krige D; Pepper C; Burnett A
Leuk Res; 2011 May; 35(5):677-81. PubMed ID: 21145592
[TBL] [Abstract][Full Text] [Related]
17. Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening.
Houshmand M; Soleimani M; Atashi A; Saglio G; Abdollahi M; Nikougoftar Zarif M
Tissue Eng Part C Methods; 2017 Feb; 23(2):72-85. PubMed ID: 28007011
[TBL] [Abstract][Full Text] [Related]
18. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
19. The bone marrow microenvironment is a critical player in the NK cell response against acute myeloid leukaemia in vitro.
Vasold J; Wagner M; Drolle H; Deniffel C; Kütt A; Oostendorp R; Sironi S; Rieger C; Fiegl M
Leuk Res; 2015 Feb; 39(2):257-62. PubMed ID: 25542695
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival.
Moshaver B; van der Pol MA; Westra AH; Ossenkoppele GJ; Zweegman S; Schuurhuis GJ
Leuk Lymphoma; 2008 Jan; 49(1):134-48. PubMed ID: 17926185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
